Erratum: GluN2B subunit-containing NMDA receptor antagonists prevent Aß-mediated synaptic plasticity disruption in vivo (Proceedings of the National Academy of Sciences of the United States America (2009) 106, (20504-20509) DOI: 10.1073/pnas.0908083106);GluN2B subunit-containing NMDA receptor antagonists prevent Aβ-mediated synaptic plasticity disruption in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 48, 2009, Pages 20504-20509

  Hu, Neng Wei ^a   Klyubin, Igor ^a   Anwy, Roger ^a   Rowan, Michael J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer's disease; Amyloid protein oligomers; Glutamate

Indexed keywords

1 (PHENATHRENYL 3 CARBONYL)PIPERAZINE 2,3 DICARBOXYLIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CYTOKINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR ANTAGONIST GLUN2B; IFENPRODIL; INFLIXIMAB; MVPAAM 077; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHOSPHONIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UBP 141; UNCLASSIFIED DRUG; [( 1 ( 4 BROMO PHENYL)ETHYLAMINO]( 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YL)METHYL]PHOSPHONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HIPPOCAMPUS; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; MEDIATOR; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; SYNAPSE; SYNAPTIC TRANSMISSION;

EID: 73949133583     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1007564107     Document Type: Erratum

References (72)

1. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45:583-595.
2. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112.
3. Lambert MP, et al. (1998) Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
4. Shankar GM, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842.
5. Raina P, et al. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 148:379-397.
6. Klyubin I, et al. (2009) Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging, In press.
7. Paoletti P, Neyton J (2007) NMDA receptor subunits: Function and pharmacology. Curr Opin Pharmacol 7:39-47.
8. Collingridge GL, Olsen R, Peters JA, Spedding M (2009) Ligand gated ion channels. Neuropharmacology 56:1.
9. Abbott JJ, Howlett DR, Francis PT, Williams RJ (2008) Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol Aging 29:992-1001.
10. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J (2009) A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 29:4004-4015.
11. Li S, et al. (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62:788-801.
12. Roselli F, et al. (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25:11061-11070.
13. Snyder EM, et al. (2005) Regulation ofNMDAreceptor trafficking by amyloid-beta. Nat Neurosci 8:1051-1058.
14. Bartlett TE, et al. (2007) Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus. Neuropharmacology 52:60-70.
15. Berberich S, Jensen V, Hvalby O, Seeburg PH, Kohr G (2007) The role of NMDAR subtypes and charge transfer during hippocampal LTP induction. Neuropharmacology 52:77-86.
16. Fox CJ, Russell KI, Wang YT, Christie BR (2006) Contribution of NR2A and NR2B NMDA subunits to bidirectional synaptic plasticity in the hippocampus in vivo. Hippocampus 16:907-915.
17. Liu L, et al. (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304:1021-1024.
18. Domingues A, Almeida S, da Cruz e Silva EF, Oliveira CR, Rego AC (2007) Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits. Neurochem Int 50:872-880.
19. Kotermanski SE, Johnson JW (2009) Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neurosci 29:2774-2779.
20. Wrighton DC, Baker EJ, Chen PE, Wyllie DJA (2008) Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. 586:211-225.
21. Bresink I, et al. (1996) Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol 119:195-204.
22. Wang Q, Wu J, Rowan MJ, Anwyl R (2005) Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 22:2827-2832.
23. Floden AM, Li S, Combs CK (2005) Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25:2566-2575.
24. Morley RM TH, Feng B, Miller JC, Monaghan DT, Jane DE (2005) Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem 48:2627-2637.
25. Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301-1317.
26. Li R, et al. (2004) Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J Neurosci 24:1760-1771.
27. Kraft AD, McPherson CA, Harry GJ (2009) Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology: doi:10.1016/j.neuro. 2009.1007.1001.
28. Lisman JE (2009) The pre/post LTP debate. Neuron 63:281-284.
29. HuNW,Smith IM,Walsh DM, RowanMJ(2008) Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain 131:2414-2424.
30. Al-Hallaq RA, Conrads TP, Veenstra TD, Wenthold RJ (2007) NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J Neurosci :8334-8343.
31. Romberg C, et al. (2009) Induction and expression of GluA1 (GluR-A)-independent LTP in the hippocampus. Eur J Neurosci 29:1141-1152.
32. von Engelhardt J, et al. (2008) Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron 60:846-860.
33. Higgins GA, Ballard TM, Enderlin M, Haman M, Kemp JA (2005) Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl) 179:85-98.
34. Mathur P, Graybeal C, Feyder M, Davis MI, Holmes A (2009) Fear memory impairing effects of systemic treatment with theNMDANR2B subunit antagonist, Ro 25-6981, in mice: Attenuation with ageing. Pharmacol Biochem Behav 91:453-460.
35. Merchant RE, et al. (1999) A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann N Y Acad Sci 890:42-50.
36. Coan EJ, Irving AJ, Collingridge GL (1989) Low-frequency activation of the NMDA receptor system can prevent the induction of LTP. Neurosci Lett 105:205-210.
37. Kelly BL, Ferreira A (2006) beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 281:28079-28089.
38. Molnar Z, et al. (2004) Enhancement of NMDA responses by beta-amyloid peptides in the hippocampus in vivo. Neuroreport 15:1649-1652.
39. Szegedi V, Juhasz G, Budai D, Penke B (2005) Divergent effects of Abeta1-42 on ionotropic glutamate receptor-mediated responses in CA1 neurons in vivo. Brain Res 1062:120-126.
40. Wu J, Anwyl R, Rowan MJ (1995) beta-Amyloid selectively augments NMDA receptormediated synaptic transmission in rat hippocampus. Neuroreport 6:2409-2413.
41. De Felice FG, et al. (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601.
42. Izumi Y, Auberson YP, Zorumski CF (2006) Zinc modulates bidirectional hippocampal plasticity by effects on NMDA receptors. J Neurosci 26:7181-7188.
43. Hooper C, et al. (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25:81-86.
44. Peineau S, et al. (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53:703-717.
45. Groc L, Bard L, ChoquetD(2009) Surface trafficking of N-methyl-D-aspartate receptors: Physiological and pathological perspectives. Neuroscience 158:4-18.
46. Martel MA, Wyllie DJ, Hardingham GE (2009) In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 158:334-343.
47. Cowburn RF, Wiehager B, Trief E, Li-Li M, Sundstrom E (1997) Effects of beta-amyloid-(25-35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: Evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor. Neurochem Res 22:1437-1442.
48. Lacor PN, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796-807.
49. Pickering M, Cumiskey D, O'Connor JJ (2005) Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 90:663-670.
50. Meda L, et al. (1995) Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374:647-650.
51. Song DK, et al. (2001) Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. J Neurochem 76:1326-1335.
52. Takeuchi H, et al. (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 281:21362-21368.
53. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: Neuroprotection by NF kappa B inhibition. Brain Res 1034:11-24.
54. Matos M, Augusto E, Oliveira CR, Agostinho P (2008) Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: Involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156:898-910.
55. Bobich JA, Zheng Q, Campbell A (2004) Incubation of nerve endings with a physiological concentration of Abeta1-42 activates CaV2.2(N-Type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. J Alzheimers Dis 6:243-255.
56. Kabogo D, Rauw G, Amritraj A, Baker G, Kar S (2008) beta-Amyloid-related peptides potentiate K(+)-evoked glutamate release from adult rat hippocampal slices. Neurobiol Aging:doi:10.1016/j.neurobiolaging. 2008.1008.1009.
57. Puzzo D, et al. (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28:14537-14545.
58. Kutsuwada T, et al. (1992) Molecular diversity of the NMDA receptor channel. Nature 358:36-41.
59. Scimemi A, Fine A, Kullmann DM, Rusakov DA (2004) NR2B-containing receptors mediate cross talk among hippocampal synapses. J Neurosci 24:4767-4777.
60. Jacob CP, et al. (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 11:97-116.
61. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40:759-766.
62. Tweedie D, Sambamurti K, Greig NH (2007) TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: New drug candidates and targets. Curr Alzheimer Res 4:375-378.
63. Buchhave P, et al. (2008) Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging In press.
64. Tan ZS, et al. (2007) Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology 68:1902-1908.
65. Tobinick E (2009) Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today 14:168-177.
66. Dantzer R, O'Connor JC, Freund GG, Johnson RW, KelleyKW(2008) From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 9:46-56.
67. Kaibara T, Leung LS (1993) Basal versus apical dendritic long-term potentiation of commissural afferents to hippocampal CA1: A current-source density study. J Neurosci 13:2391-2404.
68. Kramar EA, Lynch G (2003) Developmental and regional differences in the consolidation of long-term potentiation. Neuroscience 118:387-398.
69. Leung LS, Shen B (1999) N-methyl-D-aspartate receptor antagonists are less effective in blocking long-term potentiation at apical than basal dendrites in hippocampal CA1 of awake rats. Hippocampus 9:617-630.
70. Wang Q, et al. (2007) alphav integrins mediate beta-amyloid induced inhibition of long-term potentiation. Neurobiol Aging 29:1485-1493.
71. Wang Q, Rowan MJ, Anwyl R (2004) Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 24:6049-6056.
72. Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66:435-440.